[go: up one dir, main page]

RU2019114940A - CAPAPLEX TREATMENT - Google Patents

CAPAPLEX TREATMENT Download PDF

Info

Publication number
RU2019114940A
RU2019114940A RU2019114940A RU2019114940A RU2019114940A RU 2019114940 A RU2019114940 A RU 2019114940A RU 2019114940 A RU2019114940 A RU 2019114940A RU 2019114940 A RU2019114940 A RU 2019114940A RU 2019114940 A RU2019114940 A RU 2019114940A
Authority
RU
Russia
Prior art keywords
formula
enantiomer
compound
prevails
amount
Prior art date
Application number
RU2019114940A
Other languages
Russian (ru)
Other versions
RU2019114940A3 (en
Inventor
Мойз А. КХАЙРАЛЛАХ
Гари БРИМ
Стефен Э. БАТТС
Original Assignee
ЭРИЭЛ БАЙОФАРМА, ЭлЭлСи
ЭсКей БАЙОФАРМАСЬЮТИКАЛЗ КО., ЛТД.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51530017&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2019114940(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ЭРИЭЛ БАЙОФАРМА, ЭлЭлСи, ЭсКей БАЙОФАРМАСЬЮТИКАЛЗ КО., ЛТД. filed Critical ЭРИЭЛ БАЙОФАРМА, ЭлЭлСи
Publication of RU2019114940A publication Critical patent/RU2019114940A/en
Publication of RU2019114940A3 publication Critical patent/RU2019114940A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/02—Carbamic acids; Salts of carbamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Claims (31)

1. Способ лечения катаплексии у субъекта, который нуждается в этом, который включает введение субъекту терапевтически эффективного количества соединения формулы (I)1. A method of treating cataplexy in a subject that needs it, which comprises administering to the subject a therapeutically effective amount of a compound of formula (I)
Figure 00000001
Figure 00000001
 или его фармацевтически приемлемой соли или его сложного эфира;or a pharmaceutically acceptable salt thereof or an ester thereof; где R является элементом, выбранным из группы, состоящей из водорода, низшего алкила с количеством углеродных атомов от 1 до 8, галогена, выбранного из F, Cl, Br и I, алкокси с количеством атомов углерода от 1 до 3, нитро, гидрокси, трифторметила и тиоалкокси с количеством атомов углерода от 1 до 3;where R is an element selected from the group consisting of hydrogen, lower alkyl with the number of carbon atoms from 1 to 8, halogen, selected from F, Cl, Br and I, alkoxy with the number of carbon atoms from 1 to 3, nitro, hydroxy, trifluoromethyl and thioalkoxy with 1 to 3 carbon atoms; х является целым числом от 0 до 3, при условии, что R может быть таким же или другим, когда х равен 2 или 3;x is an integer from 0 to 3, provided that R can be the same or different when x is 2 or 3; R1 и R2 независимо выбраны из группы, содержащей водород, низший алкил с числом атомов углерода от 1 до 8, арил, арилалкил, циклоалкил с числом атомов углерода от 3 до 7; или R1 и R2 могут быть соединены с образованием 5-7-членного гетероцикла, замещенного элементом, выбранным из группы, состоящей из водорода, алкильной и арильной группы, где гетероцикл может содержать 1-2 атома азота и 0-1 атом кислорода, и в котором атомы азота непосредственно не связаны друг с другом или с атомом кислорода.R 1 and R 2 are independently selected from the group consisting of hydrogen, lower alkyl with 1 to 8 carbon atoms, aryl, arylalkyl, cycloalkyl with 3 to 7 carbon atoms; or R 1 and R 2 can be combined to form a 5-7-membered heterocycle, substituted by an element selected from the group consisting of hydrogen, an alkyl and aryl group, where the heterocycle can contain 1-2 nitrogen atoms and 0-1 oxygen atom, and in which the nitrogen atoms are not directly linked to each other or to the oxygen atom. 2. Способ по п.1, в котором x=0.2. The method according to claim 1, in which x = 0. 3. Способ по п.1, в котором R1 и R2 являются водородом, и x=0.3. The method according to claim 1, in which R 1 and R 2 are hydrogen, and x = 0. 4. Способ по п.1, в котором соединение формулы (I) является энантиомером формулы (I), практически свободным от других энантиомеров, или энатиомерной смесью, в которой преобладает один энантиомер формулы (I).4. The method according to claim 1, in which the compound of formula (I) is an enantiomer of formula (I), practically free from other enantiomers, or an enantiomeric mixture in which one enantiomer of formula (I) prevails. 5. Способ по п.4, в котором энантиомер формулы (I) преобладает в количестве вплоть до примерно 90% или больше.5. The method according to claim 4, in which the enantiomer of formula (I) prevails in an amount up to about 90% or more. 6. Способ по п.4, в котором энантиомер формулы (I) преобладает в количестве вплоть до примерно 98% или больше.6. The method according to claim 4, in which the enantiomer of formula (I) predominates in an amount up to about 98% or more. 7. Способ по п.4, в котором энантиомер формулы (I) представляет собой энантиомер формулы (Ia):7. The method according to claim 4, in which the enantiomer of formula (I) is an enantiomer of formula (Ia):
Figure 00000002
Figure 00000002
 или его фармацевтически приемлемую соль или сложный эфир.or a pharmaceutically acceptable salt or ester thereof. 8. Способ по п.7, в котором энантиомером формулы (I) является (R)- или (D)-энантиомер.8. The method according to claim 7, in which the enantiomer of formula (I) is (R) - or (D) -enantiomer. 9. Способ по п.7, в котором энантиомером формулы (Ia) является (S)- или (L)-энантиомер.9. The method according to claim 7, in which the enantiomer of formula (Ia) is (S) - or (L) -enantiomer. 10. Способ по п.7, в котором энантиомер формулы (Ia) преобладает в количестве вплоть до примерно 90% или больше.10. The method according to claim 7, in which the enantiomer of formula (Ia) prevails in an amount up to about 90% or more. 11. Способ по п.7, в котором энантиомер формулы (Ia) преобладает в количестве вплоть до примерно 98% или больше.11. The method according to claim 7, in which the enantiomer of formula (Ia) predominates in amounts up to about 98% or more. 12. Способ по п.4, в котором энантиомером формулы (I), практически свободным от других энантиомеров, является соединение формулы (Ib) или энантиомерная смесь, в которой преобладает соединение формулы (Ib):12. The method according to claim 4, in which the enantiomer of formula (I), practically free from other enantiomers, is a compound of formula (Ib) or an enantiomeric mixture in which the compound of formula (Ib) prevails:
Figure 00000003
Figure 00000003
 или его фармацевтически приемлемая соль или сложный эфир.or its pharmaceutically acceptable salt or ester. 13. Способ по п.12, в котором соединение формулы (Ib) преобладает в количестве вплоть до примерно 90% или больше.13. The method according to item 12, in which the compound of formula (Ib) prevails in an amount up to about 90% or more. 14. Способ по п.12, в котором соединение формулы (Ib) преобладает в количестве вплоть до примерно 98% или больше.14. The method according to item 12, in which the compound of formula (Ib) prevails in an amount up to about 98% or more. 15. Способ по любому из пп.1-14, в котором катаплексия связана с наркоплексией.15. The method according to any one of claims 1 to 14, in which the cataplexy is associated with narco-plexia. 16. Способ по любому из пп.1-14, в котором катаплексия является вторичной по отношению к состоянию, которое снижает уровни гипокретина у субъекта.16. The method according to any one of claims 1 to 14, in which the cataplexy is secondary to the condition that reduces the levels of hypocretin in the subject. 17. Способ по п.16, в котором состояние выбрано из группы, состоящей из опухоли головного мозга, астроцитомы, глиобластомы, глиомы, субэпендимомы, краниофарингиомы, артериовенозной мальформации, ишемической патологии, рассеянного склероза, травмы головы, операции на головном мозге, паранеопластических синдромов, болезни Ниманна-Пика типа С и энцефалита.17. The method of claim 16, wherein the condition is selected from the group consisting of a brain tumor, astrocytoma, glioblastoma, glioma, subependymoma, craniopharyngioma, arteriovenous malformation, ischemic pathology, multiple sclerosis, head injury, brain surgery, paraneoplastic syndromes , Niemann-pick disease type C and encephalitis. 18. Способ по любому из пп.1-14, в котором терапевтически эффективное количество соединения формулы (I) составляет примерно от 0,01 мг/кг/доза до примерно 150 мг/кг/доза.18. The method according to any one of claims 1 to 14, in which the therapeutically effective amount of the compound of formula (I) is from about 0.01 mg / kg / dose to about 150 mg / kg / dose. 19. Способ по любому из пп.1-14, в котором терапевтически эффективное количество соединения формулы (I) составляет примерно от 1 мг/день до примерно 7000 мг/день.19. The method according to any one of claims 1 to 14, in which a therapeutically effective amount of the compounds of formula (I) is from about 1 mg / day to about 7000 mg / day. 20. Способ по любому из пп.1-14, в котором соединение формулы (I) вводят перорально.20. The method according to any one of claims 1 to 14, in which the compound of formula (I) is administered orally. 21. Способ по любому из пп.1-14, в котором соединение формулы (I) вводят в виде капсулы или таблетки.21. The method according to any one of claims 1 to 14, in which the compound of formula (I) is administered in the form of a capsule or tablet. 22. Способ по любому из пп.1-14, где соединение формулы (I) вводят в виде капсулы в дозе от примерно 150 мг до примерно 300 мг без каких-либо вспомогательных веществ.22. The method according to any one of claims 1 to 14, where the compound of formula (I) is administered in the form of a capsule in a dose of from about 150 mg to about 300 mg without any excipients.
RU2019114940A 2013-03-13 2014-03-12 CAPAPLEX TREATMENT RU2019114940A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361778998P 2013-03-13 2013-03-13
US61/778,998 2013-03-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2015143610A Division RU2689984C2 (en) 2013-03-13 2014-03-12 Cataplexis treatment

Publications (2)

Publication Number Publication Date
RU2019114940A true RU2019114940A (en) 2019-06-28
RU2019114940A3 RU2019114940A3 (en) 2019-12-25

Family

ID=51530017

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2015143610A RU2689984C2 (en) 2013-03-13 2014-03-12 Cataplexis treatment
RU2019114940A RU2019114940A (en) 2013-03-13 2014-03-12 CAPAPLEX TREATMENT

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2015143610A RU2689984C2 (en) 2013-03-13 2014-03-12 Cataplexis treatment

Country Status (21)

Country Link
US (7) US9359290B2 (en)
EP (1) EP2968208B1 (en)
JP (2) JP6530741B2 (en)
KR (1) KR102192554B1 (en)
CN (1) CN105431142B (en)
AU (1) AU2014248849B2 (en)
BR (1) BR112015022197B1 (en)
CA (1) CA2905457A1 (en)
DK (1) DK2968208T3 (en)
ES (1) ES2927675T3 (en)
HR (1) HRP20221018T1 (en)
HU (1) HUE060060T2 (en)
MX (1) MX381381B (en)
MY (1) MY177740A (en)
PH (1) PH12015502075B1 (en)
PT (1) PT2968208T (en)
RU (2) RU2689984C2 (en)
SG (1) SG11201507121RA (en)
SI (1) SI2968208T1 (en)
TW (2) TWI663971B (en)
WO (1) WO2014164969A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8440715B2 (en) * 2005-06-08 2013-05-14 Sk Biopharmaceuticals Co., Ltd. Treatment of sleep-wake disorders
KR102021075B1 (en) 2009-06-22 2019-11-04 에스케이바이오팜 주식회사 Methods for treating or preventing fatigue
HRP20221018T1 (en) * 2013-03-13 2023-01-06 Jazz Pharmaceuticals Ireland Limited Treatment of cataplexy
ES2812586T3 (en) 2013-07-18 2021-03-17 Jazz Pharmaceuticals Ireland Ltd Treatment for obesity
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (en) 2016-07-22 2017-11-30 Flamel Ireland Ltd FORMULATIONS OF GAMMA-MODIFIED RELEASE HYDROXIBUTIRATE WITH IMPROVED PHARMACOCINETICS
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US10195151B2 (en) * 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
CN109996540A (en) 2016-09-06 2019-07-09 爵士制药国际Iii有限公司 (R) solvate forms of -2- amino -3- Phenylpropylamino formic acid esters
ES2964943T3 (en) 2016-10-06 2024-04-10 Axsome Malta Ltd Carbamoylphenylalaninol compounds for medical use
MY203401A (en) 2017-06-02 2024-06-26 Jazz Pharmaceuticals Ireland Ltd Methods and compositions for treating excessive sleepiness
US11413264B2 (en) 2017-07-31 2022-08-16 Jazz Pharmaceuticals Ireland Limited Carbamoyl phenylalaninol analogs and uses thereof
WO2019055369A1 (en) * 2017-09-12 2019-03-21 Ovid Therapeutics Inc. Use of gaboxadol in the treatment of narcolepsy
JP2021512165A (en) 2018-01-29 2021-05-13 コグノス・セラピューティクス・インコーポレイテッド Intratumoral delivery of bortezomib
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US20200147093A1 (en) * 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
PE20211199A1 (en) * 2018-10-15 2021-07-01 Axsome Therapeutics Inc USE OF REBOXETIN FOR THE TREATMENT OF NARCOLEPSY
WO2021113163A1 (en) * 2019-12-03 2021-06-10 Axsome Therapeutics, Inc. Use of reboxetine to treat nervous system disorders
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
CN113473980A (en) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 Gamma-hydroxybutyrate compositions with improved pharmacokinetics in fed state
IL293536A (en) * 2019-12-03 2022-08-01 Axsome Therapeutics Inc Use of reboxetine to treat nervous system disorders
TW202139986A (en) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 Methods of treating idiopathic hypersomnia
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
KR102390194B1 (en) * 2020-08-03 2022-04-25 셀라이온바이오메드 주식회사 A composition for treating Kca3.1 channel mediated diseases comprising phenylalkyl carbamate compounds
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
WO2025006965A1 (en) 2023-06-29 2025-01-02 Axsome Therapeutics, Inc. Methods of administering solriamfetol to lactating women
WO2025042959A1 (en) * 2023-08-21 2025-02-27 Axsome Therapeutics, Inc. Use of solriamfetol for the treatment of orphan diseases

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US178429A (en) * 1876-06-06 Improvement in hulling-machines
NZ314570A (en) 1993-06-10 2000-11-24 Lilly Co Eli Treatment of emesis using tetrahydrobenz[cd]indole-6-carboxamides
KR100197892B1 (en) 1994-09-09 1999-06-15 남창우 Novel phenylalkylaminoalcohol carbamates and process for preparing the same
KR0173862B1 (en) 1995-02-11 1999-04-01 조규향 O-carbamoyl- (D) -phenylalaninol compounds and their pharmaceutically useful salts and methods for their preparation
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173863B1 (en) 1995-04-10 1999-04-01 조규향 O-carbamoyl-phenylalanineol compounds having substituents on phenyl, pharmaceutically useful salts thereof, and preparation methods thereof
WO1998015526A1 (en) 1996-10-10 1998-04-16 Sk Corporation O-carbamoyl-phenylalaninol compounds, their pharmaceutically useful salts and process for preparing the same
AU4674797A (en) 1996-10-22 1998-05-15 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
US6204245B1 (en) 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
GB0109103D0 (en) * 2001-04-11 2001-05-30 Pfizer Ltd Novel compounds
US20030207857A1 (en) 2001-04-11 2003-11-06 Adam Mavis D. Phenyl heterocyclyl ethers
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
DE602005025222D1 (en) * 2004-03-31 2011-01-20 Janssen Pharmaceutica Nv Heterocyclic nonimidazole compounds as histamine H3 receptor modulators
WO2006029155A2 (en) * 2004-09-07 2006-03-16 Orphan Medical, Inc. Improved ghb compositions
AU2005302589B2 (en) 2004-10-28 2010-09-16 Sk Biopharmaceuticals Co., Ltd. Adjunctive therapy for depression
US8440715B2 (en) * 2005-06-08 2013-05-14 Sk Biopharmaceuticals Co., Ltd. Treatment of sleep-wake disorders
WO2007001841A1 (en) 2005-06-22 2007-01-04 Sk Holdings Co., Ltd. Treatment of sexual dysfunction
AU2005335241B9 (en) 2005-07-26 2012-12-20 Sk Biopharmaceuticals Co., Ltd. Methods for treating substance-related disorders
FR2903904A1 (en) * 2006-07-21 2008-01-25 Bioprojet Soc Civ Ile ASSOCIATION OF MODAFINIL AND AN ANTAGONIST OR REVERSE H3 RECEPTOR AGONIST
EA200970377A1 (en) 2006-10-13 2009-10-30 Янссен Фармацевтика Нв COMPOSITIONS OF PHENYLCALAMINOCARBAMATE
WO2008055313A1 (en) * 2006-11-10 2008-05-15 Dimerix Bioscience Pty Ltd Detection system and uses therefor
KR102021075B1 (en) * 2009-06-22 2019-11-04 에스케이바이오팜 주식회사 Methods for treating or preventing fatigue
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
US8927602B2 (en) 2009-11-06 2015-01-06 Sk Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
KR101783632B1 (en) 2009-11-06 2017-10-10 에스케이바이오팜 주식회사 Methods for treating Attention-Deficit/Hyperactivity Disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
HRP20221018T1 (en) * 2013-03-13 2023-01-06 Jazz Pharmaceuticals Ireland Limited Treatment of cataplexy

Also Published As

Publication number Publication date
RU2015143610A (en) 2017-04-20
US20190218174A1 (en) 2019-07-18
MX2015012644A (en) 2016-06-21
HRP20221018T1 (en) 2023-01-06
TW201919606A (en) 2019-06-01
PH12015502075A1 (en) 2016-01-18
TWI684450B (en) 2020-02-11
TWI663971B (en) 2019-07-01
US20160250176A1 (en) 2016-09-01
HK1219236A1 (en) 2017-03-31
US11713292B2 (en) 2023-08-01
JP2019147830A (en) 2019-09-05
EP2968208B1 (en) 2022-07-20
JP2016512531A (en) 2016-04-28
EP2968208A4 (en) 2016-10-12
US9359290B2 (en) 2016-06-07
US11072579B2 (en) 2021-07-27
US10259780B2 (en) 2019-04-16
RU2019114940A3 (en) 2019-12-25
MY177740A (en) 2020-09-23
US20220017457A1 (en) 2022-01-20
KR102192554B1 (en) 2020-12-18
BR112015022197A2 (en) 2017-07-18
US20140275244A1 (en) 2014-09-18
US12162821B2 (en) 2024-12-10
WO2014164969A1 (en) 2014-10-09
JP6530741B2 (en) 2019-06-12
CA2905457A1 (en) 2014-10-09
BR112015022197B1 (en) 2022-06-07
TW201513856A (en) 2015-04-16
US20230416195A1 (en) 2023-12-28
US20250059135A1 (en) 2025-02-20
CN105431142B (en) 2019-04-26
MX381381B (en) 2025-03-12
ES2927675T3 (en) 2022-11-10
HUE060060T2 (en) 2023-01-28
US20170137375A1 (en) 2017-05-18
BR112015022197A8 (en) 2019-11-26
PT2968208T (en) 2022-10-28
RU2015143610A3 (en) 2018-03-21
KR20150139522A (en) 2015-12-11
DK2968208T3 (en) 2022-08-22
SG11201507121RA (en) 2015-10-29
CN105431142A (en) 2016-03-23
AU2014248849B2 (en) 2018-08-30
EP2968208A1 (en) 2016-01-20
AU2014248849A1 (en) 2015-10-08
PH12015502075B1 (en) 2016-01-18
US9585863B2 (en) 2017-03-07
RU2689984C2 (en) 2019-05-30
SI2968208T1 (en) 2023-02-28

Similar Documents

Publication Publication Date Title
RU2019114940A (en) CAPAPLEX TREATMENT
JP2016512531A5 (en)
PH12018550049A1 (en) Protein kinase inhibitor, preparation method and medical use thereof
JP2019524883A5 (en)
JP2012530779A5 (en)
JP2016518437A5 (en)
JP2015511638A5 (en)
RU2016105436A (en) NEUROACTIVE STEROIDS, COMPOSITIONS AND THEIR USE
MA38323B1 (en) Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
RU2015143841A (en) HDAC INHIBITORS
JP2016525121A5 (en)
JP2013533253A5 (en)
RU2012101947A (en) METHODS FOR TREATING AND PREVENTING FATIGUE
RU2012109554A (en) LIGANDS OF SIGMA RECEPTORS FOR PREVENTION OR TREATMENT OF PAIN CAUSED BY CHEMOTHERAPY
JP2021046404A5 (en)
RU2013108348A (en) CONDENSED HETEROARILS AND THEIR APPLICATION
JP2017505293A5 (en)
JP2018510138A5 (en)
JP2019520344A5 (en)
RU2019121926A (en) CDK4 / 6 inhibitor
RU2014129508A (en) NEW COMBINATION
JP2019529460A5 (en)
JP2015516419A5 (en)
JP2019533007A5 (en)
JP2019516726A5 (en)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20201012